OOIR: Observatory of International Research

Papers

(The TQCC of European Journal of Drug Metabolism and Pharmacokinetics is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Pharmacokinetics and Bioavailability Study of a Novel Smoothened Inhibitor TPB15 for Treatment of Triple-Negative Breast Cancer in Rats by High Performance Liquid Chromatography-Mass Spectrometry	68
Severe 5-Fluorouracil-Associated Gastrointestinal Toxicity Unexplained by Dihydropyrimidine Dehydrogenase Deficiency and Renal Impairment: Should We Be Investigating Other Elimination Pathways to Asse	31
Acknowledgement to Referees	31
Pharmacokinetic and Pharmacodynamic Interaction of Finerenone with Diltiazem, Fluconazole, and Ritonavir in Rats	26
Development, Physicochemical Characteristics and Pharmacokinetics of a New Sustained-Release Bilayer Tablet Formulation of Tramadol with an Immediate-Release Component for Twice-Daily Administration	24
Pharmacokinetics of 4-Hydroxybenzaldehyde in Normal and Cerebral Ischemia–Reperfusion Injury Rats Based on Microdialysis Technique	23
Pharmacokinetic Study of Ultrasmall Superparamagnetic Iron Oxide Nanoparticles HY-088 in Rats	19
Plasma Distribution of Methotrexate and Its Polyglutamates in Pediatric Acute Lymphoblastic Leukemia: Preliminary Insights	17
Pharmacokinetic and Pharmacodynamic Properties of Indole-3-carbinol in Experimental Focal Ischemic Injury	17
Clinical Pharmacokinetics and Pharmacodynamics of Esaxerenone, a Novel Mineralocorticoid Receptor Antagonist: A Review	17
Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian Subjects	16
Population Pharmacokinetic Modeling and Dose Optimization of Acetaminophen and its Metabolites Following Intravenous Infusion in Critically ill Adults	15
The Effects of AT-533 and AT-533 gel on Liver Cytochrome P450 Enzymes in Rats	15
Integrated Population Pharmacokinetic Analysis of Ustekinumab Across Multiple Immune-Mediated Inflammatory Disease Populations and Healthy Subjects	14
Therapeutic Drug Monitoring of Lacosamide in Chinese Pediatric Patients with Epilepsy: Efficacy and Factors Influencing the Plasma Concentration	14
Assessment of Piperacillin–Tazobactam Population Pharmacokinetic Models in Neonates: An External Validation	13
Optimizing Antibiotic Therapy for Intravenous Drug Users: A Narrative Review Unraveling Pharmacokinetics/Pharmacodynamics Challenges	13
In Vitro Evaluation of P-gp-Mediated Drug–Drug Interactions Using the RPTEC/TERT1 Human Renal Cell Model	13
Defining the Importance of Age-Related Changes in Drug Clearance to Optimizing Aminoglycoside Dosing Regimens for Adult Patients with Cystic Fibrosis	13
Novel Techniques and Models for Studying the Role of the Gut Microbiota in Drug Metabolism	13
Pharmacokinetics, Mass Balance and Metabolism of [14C]HSK21542, a Novel Kappa Opioid Receptor Agonist, in Humans	12
Pharmacokinetics of Oral Rebaudioside A in Patients with Type 2 Diabetes Mellitus and Its Effects on Glucose Homeostasis: A Placebo-Controlled Crossover Trial	12
Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (QelbreeTM) in Healthy Adult Subjects	11
Characterization of the Stereoselective Disposition of Bupropion and Its Metabolites in Rat Plasma and Brain	11
Prediction of First-in-Human Dose of Chimeric Antigen Receptor-T (CAR-T) Cells from Mice	10

Correction to: Bioavailability of a Capsaicin Lipid Multi‑particulate Formulation in Rats	10
Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions	9
Mass Balance Recovery, Absorption, Metabolism, and Excretion of Elinzanetant in Healthy Human Volunteers and in vitro Biotransformation	9
Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer	9
Response to Comment on “Interchangeability Between Generic and Reference Products: Limits of Average Bioequivalence Methodology”	9
Whole Body Physiologically Based Pharmacokinetic Model to Explain A Patient With Drug–Drug Interaction Between Voriconazole and Flucloxacillin	8
Is Monitoring of the Intracellular Active Metabolite Levels of Nucleobase and Nucleoside Analogs Ready for Precision Medicine Applications?	8
Critical Care Pharmacology of Antiretroviral Therapy in Adults	8
Acyclovir Brain Disposition: Interactions with P-gp, Bcrp, Mrp2, and Oat3 at the Blood–Brain Barrier	8
Relationship Between Serum Ustekinumab Trough Concentration and Clinical and Biochemical Disease Activity: A Real-World Study in Adult Patients with Crohn’s Disease	8
Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity	8
Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR Pseudomonas aeruginosa Infections: An Observational Study	7
Pharmacokinetics, Safety Profile, and Tolerability of Tetramethylpyrazine Nitrone Tablets After Single and Multiple Ascending Doses in Healthy Chinese Volunteers	7
Oral Antibiotics in Patients with Short Bowel Syndrome: Hurdles and Caveats	7
Precision Medicine Strategies to Improve Isoniazid Therapy in Patients with Tuberculosis	7
A Population Pharmacokinetic Model of Whole-Blood and Intracellular Tacrolimus in Kidney Transplant Recipients	7
Assessment of Pharmacokinetic Parameters of Daidzein-Containing Nanosuspension and Nanoemulsion Formulations After Oral Administration to Rats	7
Preclinical and Clinical Pharmacokinetics and Bioavailability in Healthy Volunteers of a Novel Formulation of the Selective P2X3 Receptor Antagonist Eliapixant	7
Evaluation of the Effect of Ticagrelor Dose Interruption and Treatment Resumption with or without Bolus Doses Through Population PK/PD Simulation	6
In Vitro Ciclopirox Glucuronidation in Liver Microsomes from Humans and Various Experimental Animals	6
Risk Factors Associated with Suboptimal Tobramycin Levels in the Medical Intensive Care Unit	6
Population Pharmacokinetic Model for Unbound Concentrations of Daptomycin in Patients with MRSA Including Patients Undergoing Hemodialysis	6
Pharmacokinetic Interaction Between Imatinib and Metformin in Rats	6
mRNA-Based Nanomedicine: A New Strategy for Treating Infectious Diseases and Beyond	6
Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals	6
Model-Based Bioequivalence Analysis to Assess and Predict the Relative Bioavailability of Valproic Acid Formulations	6
Andrographis paniculata Formulations: Impact on Diterpene Lactone Oral Bioavailability	6
Pharmacokinetic Parameters of Recombinant Human Cyclophilin A in Mice	6
Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study	5
A Phase I, Open-Label, Mass Balance Study of [14C]-Iberdomide in Healthy Subjects	5
Pharmacokinetics of Imatinib Mesylate and Development of Limited Sampling Strategies for Estimating the Area under the Concentration–Time Curve of Imatinib Mesylate in Palestinian Patients with Chroni	5
Exploring the Pharmacokinetic Profile of Antiretroviral Efavirenz in Low Protein Malnourished Condition in Wistar Rats	5
Development of a 2D-QSAR Model for Tissue-to-Plasma Partition Coefficient Value with High Accuracy Using Machine Learning Method, Minimum Required Experimental Values, and Physicochemical Descriptors	5
Effects and Mechanism of Action of Panax notoginseng Saponins on the Pharmacokinetics of Warfarin	5
Pharmacokinetics of Dasatinib in Rats: a Potential Food–Drug Interaction with Naringenin	5
Nano Drug Delivery Strategies for an Oral Bioenhanced Quercetin Formulation	5
Predictive Potential of BCS and Pharmacokinetic Parameters on Study Outcome: Analysis of 198 In Vivo Bioequivalence Studies	5
The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug I	5
Comparative Pharmacokinetics of Commercially Available Cannabidiol Isolate, Broad-Spectrum, and Full-Spectrum Products	5
Preclinical Pharmacokinetics and in vitro Metabolism of FHND5071, a Novel Selective RET Kinase Inhibitor	5
Comparison of In Vitro Corneal Permeation and In Vivo Ocular Bioavailability in Rabbits of Three Marketed Latanoprost Formulations	5
Determination of Intrinsic Clearance and Fraction Unbound in Human Liver Microsomes and In Vitro-In Vivo Extrapolation of Human Hepatic Clearance for Marketed Central Nervous System Drugs	5
Pharmacokinetic/Pharmacodynamic Modeling of the Acute Heart Rate Effects of Delta-9 Tetrahydrocannabinol and Its Major Metabolites After Intravenous Injection in Healthy Volunteers	5
An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Oral	5
Characterization of Correction Factors to Enable Assessment of Clinical Risk from In Vitro CYP3A4 Induction Data and Basic Drug-Drug Interaction Models	5
External Validation of a Vancomycin Population Pharmacokinetic Model and Developing a New Dosage Regimen in Neonates	5
Systematic Evaluation of Osimertinib Population Pharmacokinetic Models in a Cohort of Dutch Adults with Non-Small Cell Lung Cancer	5
Drug Dosing in Critically Ill Adult Patients with Augmented Renal Clearance	5